Welcome to The Ammon-Pinizzotto Center for Women’s Mental Health at MGH. Our Center, established in 1989, has been renamed following the generous gift from Carol Ammon and Dr. Marie Pinizzotto. These resources will be used to realize the overarching mission of the Center.
This website provides a range of current information including discussion of new research findings in women’s mental health and how such investigations inform day-to-day clinical practice. Despite the growing number of studies being conducted in women’s health, the clinical implications of such work are frequently controversial, leaving patients with questions regarding the most appropriate path to follow. Providing these resources to patients and their doctors so that individual clinical decisions can be made in a thoughtful and collaborative fashion dovetails with the mission of our Center.
All pregnant women ages 18-45 are eligible to enroll in the registry. We are currently seeking both controls and those being treated with atypical antipsychotics and/ or antidepressants.
This study will involve 3 brief phone interviews over an 8-month period. The National Pregnancy Registry for Psychiatric Medications is dedicated to evaluating the safety of psychiatric medications that may be taken by women during pregnancy to treat a wide range of mood, anxiety, or psychiatric disorders. The primary goal of this Registry is to determine the frequency of major malformations, such as heart defects, cleft lip, or neural tube defects, in infants exposed to atypical antipsychotics and antidepressants during pregnancy. For more information, please call 1-866-961-2388 or e-mail firstname.lastname@example.org.
Help make the future better for many other women like you.
The MGH Center for Women’s Mental Health
Perinatal and Reproductive Psychiatry Program
Simches Research Building
185 Cambridge St Suite 2200
Boston, MA 02114
To make an appointment:
Massachusetts General Hospital Clinical Program: (617) 724-7792
Location of appointments:
Wang Ambulatory Care Center, Massachusetts General Hospital
15 Parkman St., Floor 8
Boston, MA 02114-3117
October 21, 2016
Last week, an article looking at the cognitive and motor development of children with prenatal exposure to antidepressants was published in JAMA Psychiatry. Since that time, we have received a lot of questions regarding the article and the clinical implications of its findings. When I did a quick Google search, I found 36 articles reviewing ...Read more
Press Release: Potential Treatment Option for Women Deciding to Discontinue Antidepressants During Pregnancy
October 18, 2016
Massachusetts General Hospital Efficacy Study Centers on EnBrace HR™ SUNSET, LA (PRWEB) OCTOBER 18, 2016: JayMac Pharmaceuticals is sponsoring a study at Massachusetts General Hospital to assess the efficacy of a pre-and post-natal supplement, EnBrace HR™, as a treatment for the prevention of depression in women with a history of Major Depressive Disorder who decide to discontinue ...Read more
October 18, 2016
Because postpartum psychosis is a relatively rare event, we do not have as much information on this illness as we have on postpartum depression. In addition, most of the literature we have on postpartum psychosis is not new. The American Journal of Psychiatry has just published an excellent and well-researched review on the topic online ...Read more
October 18, 2016
Ms. C is a woman with a long history of bipolar disorder, dating back to her teen years. Because she experienced recurrent hypomania and mania every time she attempted to discontinue her treatment, she and her psychiatrist decided that she would remain on her regular regimen of medications during pregnancy and the postpartum period, which ...Read more
October 12, 2016
In our clinic at the Center for Women’s Mental Health, we see a significant number of women who come in for the treatment of depression and anxiety while undergoing infertility treatment. While for some women this is the first time they have experienced depression and/or anxiety, most of the women who we see in the ...Read more
October 11, 2016
Over the years there have been multiple reports indicating that women with schizophrenia may experience worsening of their symptoms as they transition into the menopause. In addition, while schizophrenia typically has its onset in young adulthood, there is a second peak in women around menopause. Researchers have postulated that falling estrogen levels may modulate dopaminergic ...Read more